Oncology Days | Day 3 | Lung Cancer Screening
Lung cancer is the leading cause of death among both men and women. Approximately 70% of patients have advanced disease, therefore only 15% of patients are still alive 5 years after diagnosis. The NELSON trial showed that screening with low-dose CT for a high-risk patient group can help diagnose cancer early in these patients. Result, increased chances of successful and curable treatment. Our speakers will present the latest developments in lung cancer screening, will advice on how to overcome barriers in clinical implementation and improve access to screening and will share the newest technology in ultra low dose CT.
Speaker
Prof. Cornelia M. Schaefer-Prokop
Radiologist
Head of Imaging Department, Meander Medical Centre, Radboud University Medical Center, Amersfoort, Netherlands
Prof. Hannah Hazard-Jenkins
Associate Professor of Surgery at the department of Surgery WVU School of Medicine
Director of the WVU Cancer Institute Morgantown, West Virginia, USA
Dr. Santiago Viteri
Medical Oncologist and Patient Partner at UOMi Cancer Center
UOMi Cancer Center Barcelona, Spain
Prof. Mathias Prokop
Professor of Radiology and Chairman of the Department of Medical Imaging
Radboud University Medical Center, NetherlandsCourse Information
At the end of this video, viewers will be able to:
- Know the main results of screening trials thus far, especially of the NLST and the Nelson trial
- Understand the value of a mobile lung cancer program
- Understand the key stakeholders and investigators to make the mobile program work successfully
- Understand how optimizing CT technology will benefit lung cancer screening
This educational talk was created in April 2022. All information contained in this session was correct at the time of distribution.
Disclaimer: Appearing on the Canon Medical Academy does not represent a commercial partnership or interest from the speaker. The views herein do not represent the views of Canon Medical Systems Ltd.
